Efficacy and safety of everolimus for patients with focal cortical dysplasia type 2
This study tested everolimus for reducing seizures in patients with focal cortical dysplasia type 2 (FCD 2). While the drug was not more effective than a placebo for most, few patients showed better results, with some becoming seizure-free. Side effects were common but manageable. More research is needed to understand why certain patients respond better to treatment.
Authors
- Donghwa Yang (ORCID: https://orcid.org/0000-0002-1580-9406)
- Se Hee Kim (ORCID: https://orcid.org/0000-0001-7773-1942)
- Han Som Choi
- Sang‐Guk Lee (ORCID: https://orcid.org/0000-0003-3862-3660)
- Yun Ho Roh (ORCID: https://orcid.org/0000-0001-7212-5687)
- Seok‐Jin Lee (ORCID: https://orcid.org/0000-0001-7894-8510)
- Hoon‐Chul Kang (ORCID: https://orcid.org/0000-0002-3659-8847)
- Soyoung Park (ORCID: https://orcid.org/0000-0001-8656-9473)
- Min Jung Chang (ORCID: https://orcid.org/0000-0002-8408-5907)
- Jeong Ho Lee (ORCID: https://orcid.org/0000-0002-1052-1497)
- Se Hoon Kim (ORCID: https://orcid.org/0000-0001-7516-7372)
- Jongsung Hahn
- Kyung Lok Min
Institutions
- Ewha Womans University (KR)
- Korea Advanced Institute of Science and Technology (KR)
- Yonsei University (KR)
- Soonchunhyang University (KR)
- Severance Hospital (KR)
- Kangbuk Samsung Hospital (KR)
- National Health Insurance Service Ilsan Hospital (KR)
- National Health Insurance Service (KR)
- Bucheon University (KR)
- Jeonbuk National University (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Epilepsia Open
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1002/epi4.13104
- Citations
- 5
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.93
Funders
- Novartis
- Korea Health Industry Development Institute